报价延迟最少15分钟:2024/12/23 22:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.78 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.34/-0.56
|
|
企业价值
324.93M
|
| 资产负债 |
|
每股账面净值
2.52
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.29M
|
|
每股收益
0.76
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/12/23 22:15 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia. |